Opioids and Cabotegravir Drug Interaction in HIV PrEP Users
Official title: Title: Pharmacokinetic, pharmacodynamic , and toxicological interactions among Opioids and Cabotegravir
Funded at Florida International University · NIH-11394493 · Data updated 2026-11-12
This grant studies how opioids and cabotegravir might interact in people at risk for HIV who are on PrEP, to understand potential safety issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida International University NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project start | September 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $688,491 |
| NIH project number | 5R01DA057145-05 |
| Project ID | NIH-11394493 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with opioid use disorders who are on PrEP or have high risk of HIV exposure and may receive cabotegravir as part of PrEP or treatment.
✕Less likely to help
People not using opioids or not on PrEP may not directly benefit from this specific interaction study.
What this research studies
If you are living with HIV or using PrEP while receiving opioid treatment, this research looks at how opioid use could change the way cabotegravir and related medicines behave in your body. The team will examine how metabolic enzymes process these drugs and whether the combination could lead to higher toxicity or bursts of inflammation in the brain. They will use available models and data to explore real-world scenarios and focus on reducing potential adverse drug interactions. The goal is to inform safer pain management and HIV prevention strategies for people who use opioids.
Why it matters
Potential benefit: If successful, the work could lead to safer prescribing practices and better protection against HIV for people who use opioids.
How similar studies have gone: Prior work has shown that drug interactions can alter effects; this study addresses a specific opioid–cabotegravir combination that has not been clearly characterized.
Where this research is happening
-
Florida International University
Miami, United States Active
Researchers
- Principal investigator: El-Hage, Nazira — Florida International University
- Study coordinator: El-Hage, Nazira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.